All SpecialtiesChronic Disease #VisualAbstract Fondazione Italiana Linfomi (FIL) Phase 3 trial: Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation (HSCT) in mantle cell lymphoma improves progression-free survival (PFS) January 8, 2021 | Kathleen Lau Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print RELATED ARTICLESMORE FROM AUTHOR Sitagliptin may reduce acute graft-versus-host disease following allogeneic stem-cell transplantation Schoolchildren aged 6-8 years experiencing increased prevalence of myopia following house confinement from COVID-19 Oral azacytidine maintenance therapy improved survival outcomes in patients with acute myeloid leukemia
